|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:Company
gptkb:Emperor
|
|
gptkbp:acquisition
|
gptkb:Zymeworks
gptkb:Archer_DX
gptkb:Kymab
gptkb:Tetra_Logic_Pharmaceuticals
gptkb:Ti_Genix
gptkb:ancient_city
gptkb:Apexigen
gptkb:Shire_plc
gptkb:Hikma_Pharmaceuticals
gptkb:Talecris_Biotherapeutics
gptkb:Alder_Bio_Pharmaceuticals
gptkb:Nant_Kwest
gptkb:Envivo_Pharmaceuticals
gptkb:Wave_Life_Sciences
Ligo Cyte Pharmaceuticals
Acerta Pharma
Hikma Pharmaceuticals (part of)
|
|
gptkbp:advertising
|
gptkb:Kiyoshi_Saito
|
|
gptkbp:alliance
|
gptkb:Nasu_clan
|
|
gptkbp:allies
|
Various clans
|
|
gptkbp:annual_report
|
published
|
|
gptkbp:associated_with
|
gptkb:Uesugi_clan
|
|
gptkbp:battle
|
gptkb:Uesugi_at_Kawanakajima
|
|
gptkbp:ceo
|
gptkb:Christophe_Weber
|
|
gptkbp:clinical_trial
|
gptkb:Japan
ongoing
|
|
gptkbp:collaboration
|
rare diseases research
|
|
gptkbp:conducts_research_on
|
gptkb:Andrew_Plump
|
|
gptkbp:conflict
|
Uesugi-Takeda conflicts
|
|
gptkbp:cultural_impact
|
Japanese history
|
|
gptkbp:descendant
|
gptkb:Takeda_clan
|
|
gptkbp:employees
|
over 50,000
50,000+
|
|
gptkbp:famous_for
|
gptkb:Battle_of_Mikatagahara
|
|
gptkbp:focus_area
|
gastroenterology
|
|
gptkbp:founded
|
1781
|
|
gptkbp:founder
|
gptkb:Chobei_Takeda_I
|
|
gptkbp:global_presence
|
over 70 countries
|
|
gptkbp:headquarters
|
gptkb:Osaka,_Japan
|
|
gptkbp:historical_figure
|
gptkb:Takeda_Shingen
|
|
gptkbp:historical_period
|
gptkb:Sengoku_period
|
|
gptkbp:historical_significance
|
Warlord rivalry
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Takeda
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
Pharmaceuticals
|
|
gptkbp:invention
|
over 2,000
|
|
gptkbp:legacy
|
gptkb:military_strategy
|
|
gptkbp:market
|
global
|
|
gptkbp:notable_battle
|
gptkb:Battle_of_Kawanakajima
|
|
gptkbp:notable_leader
|
gptkb:Takeda_Shingen
|
|
gptkbp:notable_member
|
gptkb:Takeda_Shingen
gptkb:Takeda_Nobutora
gptkb:Takeda_Yoshinobu
|
|
gptkbp:notable_rivalry
|
gptkb:Uesugi
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Mitsubishi_Tanabe_Pharma
gptkb:Novartis
gptkb:Nant_Kwest
various academic institutions
|
|
gptkbp:philanthropy
|
gptkb:Takeda_Foundation
|
|
gptkbp:political_impact
|
Kai Province
|
|
gptkbp:products
|
Vaccines
vaccines
Oncology drugs
oncology drugs
rare disease treatments
|
|
gptkbp:region
|
gptkb:Japan
Kai Province
|
|
gptkbp:research_and_development
|
Biologics
Rare diseases
$2 billion (2020)
|
|
gptkbp:research_focus
|
oncology
rare diseases
neuroscience
gastroenterology
|
|
gptkbp:revenue
|
$30 billion (2020)
$30 billion (2022)
over $20 billion (2022)
|
|
gptkbp:rival
|
After Sengoku period
|
|
gptkbp:social_responsibility
|
sustainability initiatives
community health programs
access to medicine initiatives
|
|
gptkbp:stock_exchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:strategy
|
Offensive warfare
|
|
gptkbp:subsidiaries
|
gptkb:Takeda_Pharmaceuticals_International_AG
gptkb:Takeda_Pharmaceuticals_USA,_Inc.
|
|
gptkbp:tactics
|
Shingen's tactics
|
|
gptkbp:time_period
|
gptkb:Sengoku_period
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
|
|
gptkbp:bfsLayer
|
3
|